Genesystem Co., Ltd. (KOSDAQ:363250)
South Korea
· Delayed Price · Currency is KRW 5,500.00
-340.00 (-5.82%)
At close: Apr 28, 2026
Genesystem Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -11,955 | -8,915 | -7,915 | -8,996 |
| Depreciation & Amortization | 1,018 | 1,242 | 545.39 | 386.3 |
| Loss (Gain) From Sale of Assets | -5 | 0.18 | - | 3.14 |
| Asset Writedown & Restructuring Costs | 6,275 | - | - | - |
| Loss (Gain) From Sale of Investments | -94.84 | -194.97 | -595.61 | 380.34 |
| Loss (Gain) on Equity Investments | - | - | -545.52 | 444.93 |
| Stock-Based Compensation | 223.37 | 64.12 | 106.87 | 80.15 |
| Provision & Write-off of Bad Debts | 12.06 | 15.53 | -45.25 | 303.51 |
| Other Operating Activities | -2,021 | 804.8 | 1,088 | 2,252 |
| Change in Accounts Receivable | -24.86 | 100.38 | 405.73 | 1,163 |
| Change in Inventory | -60.27 | 240.19 | -417.85 | -1,772 |
| Change in Accounts Payable | 11.85 | -5.13 | -28.99 | -259.43 |
| Change in Unearned Revenue | - | - | -35.02 | 35.02 |
| Change in Other Net Operating Assets | -261.92 | -689 | -373.46 | -438.07 |
| Operating Cash Flow | -6,883 | -7,337 | -7,812 | -6,417 |
| Capital Expenditures | -219.66 | -258.73 | -362.85 | -238.43 |
| Sale of Property, Plant & Equipment | 5 | 0.55 | - | - |
| Cash Acquisitions | - | - | 56.11 | - |
| Sale (Purchase) of Intangibles | -114.62 | -102.37 | -55.96 | -86.86 |
| Investment in Securities | 3,008 | 5,839 | 1,274 | -2,260 |
| Other Investing Activities | 35.42 | 94.06 | 3.25 | 20.68 |
| Investing Cash Flow | 2,714 | 5,572 | -85.42 | -2,565 |
| Short-Term Debt Issued | 90 | - | - | - |
| Total Debt Issued | 90 | - | - | - |
| Long-Term Debt Repaid | -501.32 | -405.76 | -88.07 | -71.34 |
| Net Debt Issued (Repaid) | -411.32 | -405.76 | -88.07 | -71.34 |
| Issuance of Common Stock | 44.16 | 211.57 | 242.47 | 224.33 |
| Repurchase of Common Stock | - | -1,518 | - | - |
| Other Financing Activities | 25.15 | -4.31 | 24.07 | 28.32 |
| Financing Cash Flow | -342.01 | -1,716 | 178.48 | 181.32 |
| Foreign Exchange Rate Adjustments | 0.55 | 14.15 | -28.68 | 6.32 |
| Miscellaneous Cash Flow Adjustments | - | 0 | - | 0 |
| Net Cash Flow | -4,511 | -3,467 | -7,747 | -8,794 |
| Free Cash Flow | -7,103 | -7,595 | -8,174 | -6,655 |
| Free Cash Flow Margin | -1862.60% | -628.89% | -911.27% | -182.18% |
| Free Cash Flow Per Share | -1042.12 | -1109.26 | -1176.31 | -964.32 |
| Cash Interest Paid | 121.66 | 137.96 | 133.93 | 95.06 |
| Cash Income Tax Paid | -21.02 | -24.3 | 47.01 | 64.87 |
| Levered Free Cash Flow | -3,972 | -1,423 | -8,402 | - |
| Unlevered Free Cash Flow | -3,894 | -1,338 | -8,319 | - |
| Change in Working Capital | -335.2 | -353.55 | -449.58 | -1,272 |
Source: S&P Capital IQ. Standard template. Financial Sources.